Warfarin Potassium

Sold as Athrombin-K. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Warfarin Potassium (sold as Athrombin-K), with 0 new uses approved and 0 published complete response letters.

First approved: not available
Applications: 1
New uses approved: 0
Complete response letters: 0

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

WARFARIN SODIUM 1 MG TABLET: $0.102 per unitGeneric · +24% in a year
WARFARIN SODIUM 10 MG TABLET: $0.109 per unitGeneric · 0% in a year
WARFARIN SODIUM 2 MG TABLET: $0.095 per unitGeneric · +10% in a year
WARFARIN SODIUM 2.5 MG TABLET: $0.097 per unitGeneric · +6% in a year
WARFARIN SODIUM 3 MG TABLET: $0.101 per unitGeneric · +5% in a year
WARFARIN SODIUM 4 MG TABLET: $0.101 per unitGeneric · +12% in a year
WARFARIN SODIUM 5 MG TABLET: $0.089 per unitGeneric · -9% in a year
WARFARIN SODIUM 6 MG TABLET: $0.095 per unitGeneric · -9% in a year
WARFARIN SODIUM 7.5 MG TABLET: $0.088 per unitGeneric · -20% in a year

Approvals in Japan (PMDA)

PMDA's English list since 2008, matched by ingredient; see all Japanese approvals

WarfarinDrugs with new additional pediatric dosages. · Eisai Co., Ltd. · Feb 23, 2011

Clinical Trials

82 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesUlcerative Colitis, Crohn's Disease · Sanofi	Phase 1	Not yet recruiting	Nov 6, 2026
Post Pulmonary Embolism In Patients Treated With Catheter Based TherapyPulmonary Embolism Acute · Assiut University	Not applicable	Not yet recruiting	Oct 21, 2026
Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid SyndromeAntiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome · Assistance Publique - Hôpitaux de Paris	Phase 3	Not yet recruiting	Oct 15, 2026
A Study on Abnormal Menstrual Bleeding in Chinese Women of Childbearing Age Taking Antithrombotic Drugs After Cardiovascular SurgeryUterine Hemorrhage, Cardiovascular Diseases · Shanghai Zhongshan Hospital	—	Recruiting	Oct 13, 2026
Warfarin Quality, Adherence, Range, Determinants, and Events in Egyptian Rheumatic Heart Disease and Atrial FibrillationAF · Assiut University	—	Not yet recruiting	Sep 17, 2026
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or ObesityDrug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics · The United Bio-Technology (Hengqin) Co., Ltd.	Phase 1	Recruiting	Aug 25, 2026
Predicting Response and Exposure Changes in Cirrhosis for EffectivenessLiver Cirrhosis · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Not applicable	Not yet recruiting	Aug 6, 2026
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic StrokeIschemic Stroke, Transient Ischemic Attack · Asan Medical Center	Phase 3	Not yet recruiting	Jul 28, 2026

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
—	Athrombin, Athrombin-KNDA 11771	Pharm Res Assoc	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA